David A. Siegel Fsd Pharma Inc. Transaction History

Two Sigma Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$1.45 - $1.84 $17,545 - $22,264	-12,100 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.56 - $2.13 $29,484 - $40,257	-18,900 Reduced 60.97%	12,100 $21,000
Q1 2021 May 17, 2021	SELL	$1.65 - $3.87 $20,625 - $48,375	-12,500 Reduced 28.74%	31,000 $59,000
Q4 2020 Feb 16, 2021	BUY	$1.36 - $2.7 $544 - $1,080	400 Added 0.93%	43,500 $68,000
Q3 2020 Nov 16, 2020	BUY	$2.55 - $4.26 $109,904 - $183,606	43,100 New	43,100 $110,000

Ticker HUGE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 38,218,100
Market Cap $146M
Description
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.